Indications
Ranexa is indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti-anginal therapies (such as beta-blockers and / or calcium antagonists).
Composition
- Active substance
- ranolazine
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Ranexa (previously Latixa)
- Active substance
- ranolazine
- ATC code
- C01EB18
- Therapeutic area
- Angina Pectoris
- Marketing authorisation holder
- Menarini International Operations Luxembourg S.A. (MIOL)
- Status